•  
  •  
 

Turkish Journal of Medical Sciences

Author ORCID Identifier

ÇAĞDAŞ YILDIRIM: 0000-0001-7456-5395

GÜL PAMUKÇU GÜNAYDIN: 0000-0001-8531-4591

DOI

10.55730/1300-0144.5864

Abstract

Background/aimHyoscine-N-Butylbromide (HBB) is an anticholinergic agent widely used to treat pain caused by spasms in the gastrointestinal and urogenital systems. The aim of this study was to compare the efficacy of HBB with placebo in treating abdominal cramping pain caused by acute gastroenteritis in the Emergency Department (ED).Materials and methodsThis was a prospective, double-blind, placebo-controlled, randomized trial conducted in a single-center academic ED, from September to November 2021. Patients aged 18-65 years with acute gastroenteritis symptoms included in the study. The study compared the efficacy of intravenous HBB (20 mg) with placebo. The primary outcome was the absolute change in pain score at 30 minutes post-treatment, with secondary outcomes including pain relief at 60 minutes, adverse events, and the need for rescue analgesics.ResultsFifty patients were randomized (25 in each group). There was no significant difference between the groups in 30-minute and 60-minute pain scores. At 60 minutes, pain reduction and need for rescue analgesia were similar in both groups. Changes in pain scores from admission to 30 and 60 minutes did not significantly differ between groups.ConclusionIntravenous HBB, did not show a statistically or clinically significant difference in pain reduction compared to placebo in patients with acute gastroenteritis and cramping abdominal pain in the ED.

Keywords

abdominal pain, Butylscopolammonium bromide, gastroenteritis, pain management

First Page

887

Last Page

892

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Share

COinS